CA
NZ
UK
AU
IND
US
…
biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and meet other administrative requirements; inventory management software to facilitate ordering and inventory control; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female patients. The company was founded in 2012 and is headquartered in Irving, Texas.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Biote Corp operates a network of clinics and telehealth services delivering hormone optimization, diagnostics, and related practitioner training and products for adult men and women. Long-term growth could be supported by aging demographics, rising demand for personalized hormone therapy, and expansion of clinic and virtual-care footprints with recurring treatment revenue. Investors may find the company attractive for its niche in consumer-facing endocrine care that appears positioned to scale through additional locations and digital channels.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 37.58M | 1.02M | -0.12M | 1.71M | 32.91M |
| Minority interest | -4.55M | 3.11M | -0.72M | -2.29M | - |
| Net income | 27.05M | 3.16M | 3.32M | 1.32M | 32.62M |
| Selling general administrative | 101.81M | 107.45M | 93.42M | 165.50M | 49.05M |
| Selling and marketing expenses | - | - | - | 4.63M | 4.91M |
| Gross profit | 137.36M | 139.06M | 127.48M | 110.38M | 90.58M |
| Reconciled depreciation | 3.67M | 3.57M | 2.04M | 2.20M | 1.40M |
| Ebit | 35.55M | 12.02M | 38.74M | -60.72M | 34.56M |
| Ebitda | 39.22M | 15.59M | 39.54M | -57.45M | 34.58M |
| Depreciation and amortization | 3.67M | 3.57M | 0.79M | 3.27M | 0.02M |
| Operating income | 35.55M | 31.61M | 28.66M | -60.72M | 34.56M |
| Other operating expenses | 156.67M | 165.58M | 156.70M | 225.68M | 104.83M |
| Interest expense | 10.96M | 11.00M | 6.36M | 5.09M | 1.67M |
| Tax provision | 5.99M | 0.97M | 5.86M | 0.39M | 0.29M |
| Net interest income | -10.96M | -11.00M | -7.43M | -5.09M | -1.67M |
| Income tax expense | 5.99M | 0.97M | 2.68M | 0.39M | 0.29M |
| Total revenue | 192.22M | 197.19M | 185.36M | 164.96M | 139.40M |
| Total operating expenses | 101.81M | 107.45M | 98.83M | 171.10M | 56.02M |
| Cost of revenue | 54.86M | 58.13M | 57.88M | 54.58M | 48.82M |
| Total other income expense net | 2.03M | -30.59M | -28.78M | 62.43M | -1.66M |
| Net income from continuing ops | 31.60M | 0.05M | -2.07M | 1.32M | 32.62M |
| Net income applicable to common shares | - | - | - | - | 32.62M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 107.61M | 122.37M | 155.29M | 111.64M | 54.33M |
| Intangible assets | 4.27M | 9.38M | 4.97M | 5.07M | 4.55M |
| Other current assets | 4.62M | 6.24M | 4.22M | 3.82M | 3.94M |
| Total liab | 158.01M | 224.57M | 191.84M | 169.92M | 50.20M |
| Total stockholder equity | -58.54M | -105.93M | -29.40M | -44.46M | 4.12M |
| Other current liab | 28.31M | 35.97M | 8.50M | 6.27M | 6.01M |
| Common stock | 0.00M | 0.00M | 0.01M | 0.01M | 317.50M |
| Capital stock | 0.00M | 0.00M | 0.01M | 0.01M | 0.00M |
| Retained earnings | -49.55M | -100.30M | -29.39M | -44.46M | 4.17M |
| Other liab | - | - | - | 37.14M | 0.80M |
| Good will | 5.83M | 5.83M | - | - | - |
| Other assets | - | - | 0.00M | - | - |
| Cash | 24.12M | 39.34M | 89.00M | 79.23M | 26.77M |
| Total current liabilities | 44.99M | 51.51M | 22.21M | 18.77M | 17.31M |
| Current deferred revenue | 3.02M | 2.96M | 3.00M | 1.97M | 1.71M |
| Net debt | 85.80M | 71.52M | 25.87M | 41.20M | 10.57M |
| Short term debt | 6.84M | 6.77M | 6.56M | 6.42M | 5.25M |
| Short long term debt | 6.25M | 6.25M | 6.25M | 6.25M | 5.00M |
| Short long term debt total | 109.92M | 110.86M | 114.87M | 120.43M | 37.34M |
| Other stockholder equity | -8.96M | -5.60M | - | -13.81M | -317.50M |
| Property plant equipment | - | - | - | 3.56M | 2.69M |
| Total current assets | 54.67M | 68.13M | 122.34M | 101.18M | 47.09M |
| Net tangible assets | - | - | - | -49.53M | -0.43M |
| Net receivables | 6.87M | 7.70M | 8.17M | 6.95M | 5.23M |
| Long term debt | 100.78M | 101.20M | 106.63M | 112.09M | 31.96M |
| Inventory | 19.06M | 14.85M | 20.95M | 11.18M | 9.62M |
| Accounts payable | 6.83M | 5.81M | 4.16M | 4.11M | 4.35M |
| Accumulated other comprehensive income | -0.03M | -0.04M | -0.01M | -0.01M | -0.04M |
| Non currrent assets other | 4.60M | 0.07M | 4.97M | 5.07M | -317.58M |
| Non current assets total | 52.94M | 54.24M | 32.95M | 10.47M | 7.25M |
| Capital lease obligations | 2.89M | 3.41M | 1.99M | 2.09M | 0.38M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -18.80M | -22.02M | -1.84M | -3.81M |
| Change to liabilities | - | - | - | 0.38M | 1.23M |
| Total cashflows from investing activities | -6.86M | -18.80M | -2.71M | - | -3.81M |
| Net borrowings | -1.25M | -6.25M | -6.25M | 84.38M | -5.00M |
| Total cash from financing activities | -43.55M | -76.08M | -14.38M | 63.46M | -20.34M |
| Change to operating activities | - | - | - | - | 3.82M |
| Net income | 27.05M | 0.05M | 3.32M | 1.32M | 32.62M |
| Change in cash | -15.22M | -49.66M | 9.77M | 52.47M | 9.56M |
| Begin period cash flow | 39.34M | 89.00M | 79.23M | 26.77M | 17.21M |
| End period cash flow | 24.12M | 39.34M | 89.00M | 79.23M | 26.77M |
| Total cash from operating activities | 35.19M | 45.24M | 26.88M | -9.16M | 33.72M |
| Issuance of capital stock | 0.14M | 0.28M | 0.29M | 0.44M | - |
| Depreciation | 3.67M | 3.57M | 2.99M | 2.20M | 1.40M |
| Other cashflows from investing activities | -1.85M | -0.53M | -2.35M | - | - |
| Dividends paid | 1.73M | 4.74M | 8.69M | 12.89M | 11.40M |
| Change to inventory | -6.24M | 3.71M | -6.10M | -1.71M | -5.76M |
| Change to account receivables | -0.96M | -2.27M | -0.51M | -1.56M | -0.75M |
| Sale purchase of stock | -3.37M | -5.60M | 14.52M | -0.42M | - |
| Other cashflows from financing activities | -37.58M | -59.77M | 0.42M | 116.95M | -3.94M |
| Change to netincome | - | - | - | 24.84M | 0.94M |
| Capital expenditures | 5.01M | 6.43M | 2.71M | 1.84M | 3.81M |
| Change in working capital | -8.25M | 9.93M | -8.93M | -35.81M | -1.46M |
| Stock based compensation | 8.92M | 8.73M | 9.06M | 82.18M | - |
| Other non cash items | -0.17M | 25.85M | 19.72M | -58.30M | 1.16M |
| Free cash flow | 30.18M | 38.81M | 24.17M | -10.99M | 29.91M |
Sector: Healthcare Industry: Medical Care Facilities
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| BTMD biote Corp |
0.02 1.92% |
1.06 | 3.04 | 4.69 | 0.43 | 2.96 | 0.82 | 3.02 |
| HCA HCA Healthcare, Inc. |
-12.49 2.46% |
494.99 | 14.27 | 13.46 | 1.21 | 291.34 | 1.83 | 8.99 |
| THC Tenet Healthcare Corporation |
-3.13 1.09% |
283.33 | 10.08 | 12.66 | 0.96 | 4.57 | 1.43 | 5.80 |
| FSNUY Fresenius SE & Co KGaA ADR |
0.06 0.42% |
14.62 | 16.87 | 9.44 | 0.42 | 0.78 | 0.79 | 5.37 |
| JDHIY JD Health International Inc |
- -% |
5.28 | 62.50 | 35.97 | 0.30 | 2.32 | 0.16 | 3.90 |
biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and meet other administrative requirements; inventory management software to facilitate ordering and inventory control; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female patients. The company was founded in 2012 and is headquartered in Irving, Texas.
1875 W. Walnut Hill Ln #100, Irving, TX, United States, 75038
844 604 1246
223
| Name | Title | Year Born |
|---|---|---|
| Mr. Marc D. Beer | Exec. Chairman | 1965 |
| Ms. Teresa S. Weber | CEO & Director | 1953 |
| Mr. Cary M. Paulette | Chief Revenue Officer | 1962 |
| Mr. Samar Kamdar | Chief Financial Officer | 1979 |
| Mr. Joe Butler | Chief Information Officer | 1962 |
| Ms. Mary Elizabeth Conlon | VP of Bus. Devel. & Gen. Counsel | 1980 |
| Mr. Richard Kevin Key | Chief Digital Officer & Head of Marketing | 1970 |
| Ms. Jennifer Schimmel | Director of HR & Talent | 1973 |
| Mr. Jade Beutler | Head of Nutraceuticals | 1963 |
| Dr. Ross W. McQuivey M.D. | Chief Medical Officer & Member of Medical Advisory Board | 1972 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+0.61%
Communication Services
-0.21%
Consumer Cyclical
-0.26%
Consumer Defensive
-0.37%
Energy
+0.23%
Financial Services
-0.43%
Financials
+0.39%
Healthcare
+0.88%
Industrials
+0.36%
Real Estate
-0.51%
Technology
+1.35%
Utilities
+0.19%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...